Jagsonpal Pharmaceuticals launches QueeZy-ER®

Jagsonpal Pharmaceuticals Limited, a leading company operating in women healthcare segment today announced the launch of QueeZy-ER® providing relief from Nausea and Vomiting in Pregnancy (NVP).

The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation. The product comes with a tablet-intablet technology, which allows dispersal of uniform dosage at two different time-periods from the same dose, thereby allowing for 24-hour benefit to the patient. This allows for a single dose as against the conventional requirement of up to 3-4 tablets a day.

Further, the overall therapy cost per day is lower as compared to conventional pills.

The combination of Doxylamine succinate 20mg and Pyridoxine hydrochloride 20mg is the only USFDA approved combination for NVP treatment.

Key benefits of Queezy-ER®

- Extended-Release: Unique dual-release formulation for immediate and prolonged relief, reducing the need for frequent dosing

- Improved adherence: Minimizes the necessity for frequent dosing, enhancing patient compliance for a more consistent approach to symptom management

- Safety Assurance: Formulated with ingredients known for their safety profile in pregnant women, ensuring a secure and reliable option for managing symptoms

Queezy-ER® is now available in leading pharmacies across India.

Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 303.45 as compared to the previous close of Rs. 308.75. The total number of shares traded during the day was 1826 in over 132 trades.

The stock hit an intraday high of Rs. 322.60 and intraday low of 303.00. The net turnover during the day was Rs. 561527.00.

Source : Equity Bulls

Keywords

JagsonpalPharmaceuticals INE048B01027 ProductLaunch QueeZyER Nausea Vomiting Pregnancy